High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation

The protein kinase complement of the human genome

Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145 · see citing works

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676 · see citing works

Paired Helical Filaments in Electron Microscopy of Alzheimer's Disease

KIDD, M. (1963) · Nature · doi:10.1038/197192b0 · Cited by 1,012 · see citing works

Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease

Augustinack, J. C., Schneider, A., Mandelkow, E.-M., & Hyman, B. T. (2002) · Acta Neuropathologica · doi:10.1007/s004010100423 · Cited by 998 · see citing works

Tauopathy in <i>Drosophila</i> : Neurodegeneration Without Neurofibrillary Tangles

Wittmann, C. W., Wszolek, M. F., Shulman, J. M., Salvaterra, P. M., Lewis, J., Hutton, M., & Feany, M. B. (2001) · Science · doi:10.1126/science.1062382 · Cited by 939 · see citing works

Developmentally regulated expression of specific tau sequences

Kosik, K. S., Orecchio, L. D., Bakalis, S., & Neve, R. L. (1989) · Neuron · doi:10.1016/0896-6273(89)90077-9 · Cited by 598 · see citing works

Phosphorylated Tau Protein Is Integrated into Paired Helical Filaments in Alzheimer's Disease1

Ihara, Y., Nukina, N., Miura, R., & OGAWARA, M. (1986) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a135662 · Cited by 527 · see citing works

Kinomics: methods for deciphering the kinome

Johnson, S. A., & Hunter, T. R. (2004) · Nature Methods · doi:10.1038/nmeth731 · Cited by 420 · see citing works

THE FINE STRUCTURE OF NEUROFIBRILLARY TANGLES IN ALZHEIMERʼS DISEASE

Terry, R. D. (1963) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-196310000-00005 · Cited by 403 · cited 3× · see citing works

Microtubule-associated Protein/Microtubule Affinity-regulating Kinase (p110mark)

Meyer, H. E., Mandelkow, E.-M., Drewes, G., Trinczek, B., Illenberger, S., Biernat, J., Schmitt-Ulms, G., & Mandelkow, E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7679 · Cited by 388 · see citing works

α-Synuclein Binds to Tau and Stimulates the Protein Kinase A-catalyzed Tau Phosphorylation of Serine Residues 262 and 356

Jensen, P. H., Hager, H., Nielsen, M. S., Højrup, P., Gliemann, J., & Jakes, R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25481 · Cited by 377 · see citing works

Phosphorylation of Tau at Both Thr 231 and Ser 262 Is Required for Maximal Inhibition of Its Binding to Microtubules

Sengupta, A., Kabat, J., Novak, M., Wu, Q., Grundke-Iqbal, I., & Iqbal, K. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0813 · Cited by 363 · see citing works

The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bɛ at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase

Woods, Y. L., Cohen, P., Becker, W. B., Jakes, R., Goedert, M., Wang, X., & Proud, C. G. (2001) · Biochemical Journal · doi:10.1042/bj3550609 · Cited by 343 · see citing works

Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules.

Trinczek, B., Biernat, J., Baumann, K., Mandelkow, E. M., & Mandelkow, E. (1995) · Molecular Biology of the Cell · doi:10.1091/mbc.6.12.1887 · Cited by 340 · see citing works

Phosphorylation of eukaryotic initiation factor-2α (eIF2α) is associated with neuronal degeneration in Alzheimerʼs disease

Chang, R. C. C., Wong, A. K. Y., Ng, H.-K., & Hugon, J. (2002) · NeuroReport · doi:10.1097/00001756-200212200-00011 · Cited by 289 · see citing works

DYRK1A-mediated Hyperphosphorylation of Tau

Ryoo, S., Jeong, H. K., Radnaabazar, C., Yoo, J.-J., Cho, H.-J., Lee, H. W., Kim, I.-S., Cheon, Y. H., Ahn, Y. S., Chung, S., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707358200 · Cited by 285 · see citing works

The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between β-amyloid production and tau phosphorylation in Alzheimer disease

Kimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., Hashimoto, R., Tanaka, T., Kudo, T., Yamagata, H., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl437 · Cited by 281 · see citing works

The Alzheimer‐like phosphorylation of tau protein reduces microtubule binding and involves Ser‐Pro and Thr‐Pro motifs

Gustke, N., Steiner, B., Mandelkow, E., Biernat, J., Meyer, H. E., Goedert, M., & Mandelkow, E. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80767-b · Cited by 219 · see citing works

Tau Phosphorylation Sites Work in Concert to Promote Neurotoxicity In Vivo

Steinhilb, M. L., Dias-Santagata, D., Fulga, T. A., Felch, D. L., & Feany, M. B. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-04-0327 · Cited by 187 · see citing works

Regulation of neuronal PKA signaling through AKAP targeting dynamics

Dell’Acqua, M. L., Smith, K. E., Gorski, J. A., Horne, E. A., Gibson, E. S., & Gomez, L. L. (2006) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2006.01.010 · Cited by 173 · see citing works

The Role of Tau Phosphorylation in the Pathogenesis of Alzheimers Disease

Mi, K., & Johnson, G. V. W. (2006) · Current Alzheimer Research · doi:10.2174/156720506779025279 · Cited by 166 · see citing works

Tau Protein in Normal and Alzheimer's Disease Brain: An Update

Johnson, G. V. W., & Hartigan, J. A. (1999) · Journal of Alzheimer s Disease · doi:10.3233/jad-1999-14-512 · Cited by 154 · see citing works

Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356

Litersky, J. M., Johnson, G. V. W., Jakes, R., Goedert, M., Lee, M., & Seubert, P. A. (1996) · Biochemical Journal · doi:10.1042/bj3160655 · Cited by 150 · see citing works

Double-strand RNA dependent protein kinase (PKR) is involved in the extrastriatal degeneration in Parkinson's disease and Huntington's disease

BANDO, Y., ONUKI, R., KATAYAMA, T., MANABE, T., KUDO, T., TAIRA, K., & TOHYAMA, M. (2005) · Neurochemistry International · doi:10.1016/j.neuint.2004.07.005 · Cited by 126 · see citing works

Activation of the cell stress kinase PKR in Alzheimer's disease and human amyloid precursor protein transgenic mice

Peel, A. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00086-x · Cited by 125 · see citing works

Calcium/calmodulin‐dependent protein kinase II phosphorylates tau at Ser‐262 but only partially inhibits its binding to microtubules

Singh, T. J., Wang, J., Novák, M., Kontzekova, E., Grundke, I., & Iqbal, K. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00485-1 · Cited by 82 · see citing works

Tau, where are we now?

Johnson, G. V. W., & Bailey, C. D. C. (2002) · Journal of Alzheimer s Disease · doi:10.3233/jad-2002-4505 · Cited by 78 · see citing works

The Regulatory Ser262 of Microtubule-associated Protein Tau Is Phosphorylated by Phosphorylase Kinase

Paudel, H. K. (1997) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)67481-8 · Cited by 65 · see citing works

Orchestration of synaptic plasticity through AKAP signaling complexes

Bauman, A. L., Goehring, A. S., & Scott, J. D. (2003) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.09.016 · Cited by 61 · see citing works

GSK-3β Directly Phosphorylates and Activates MARK2/PAR-1

Kosuga, S., Tashiro, E., Kajioka, T., Ueki, M., Shimizu, Y., & Imoto, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507941200 · Cited by 57 · see citing works

Tau protein kinase I/GSK-3Β/kinase FA in heparin phosphorylates tau on Ser199, Thr231, Ser235, Ser262, Ser369, and Ser400 sites phosphorylated in Alzheimer disease brain

Song, J., & Yang, S. (1995) · Journal of Protein Chemistry · doi:10.1007/bf01888367 · Cited by 54 · see citing works

Double stranded RNA activated EIF2 α kinase (EIF2AK2; PKR) is associated with Alzheimer's disease

Bullido, M. J., Martínez-García, A., Tenorio, R., Sastre, I., Muñoz, D. G., Frank, A., & Valdivieso, F. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.023 · Cited by 51 · see citing works

BEYOND AMYLOID: The Next Generation of Alzheimer's Disease Therapeutics

Seabrook, G. R., Ray, W. J., Shearman, M. S., & Hutton, M. L. (2007) · Molecular Interventions · doi:10.1124/mi.7.5.8 · Cited by 48 · see citing works

Phosphorylation of microtubule-associated protein tau by Ca2+/calmodulin-dependent protein kinase II in its tubulin binding sites

Yamamoto, H., Yamauchi, E., Taniguchi, H., Ono, T., & Miyamoto, E. (2002) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(02)00556-8 · Cited by 39 · see citing works

A brief history of tau: the evolving view of the microtubule-associated protein tau in neurodegenerative diseases

Lace, G., Wharton, S. B., & Ince, P. G. (2007) · Clinical Neuropathology · doi:10.5414/npp26043 · Cited by 37 · see citing works

Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?

Mullane, K., & Williams, M. J. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 212 · see citing works

Selectivity, Cocrystal Structures, and Neuroprotective Properties of Leucettines, a Family of Protein Kinase Inhibitors Derived from the Marine Sponge Alkaloid Leucettamine B

Tahtouh, T., Elkins, J. M., Filippakopoulos, P., Soundararajan, M., Burgy, G., Durieu, É., Cochet, C., Schmid, R. S., Lo, D. C., Delhommel, F., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301034u · Cited by 203 · see citing works

β-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau Phosphorylation at Multiple Alzheimer's Disease-Related Sites

Frost, D., Meechoovet, B., Wang, T., Gately, S. T., Giorgetti, M., Shcherbakova, I. M., & Dunckley, T. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019264 · Cited by 178 · see citing works

DYRK1A and cognition: A lifelong relationship

Arbonés, M. L., Thomazeau, A., Nakano-Kobayashi, A., Hagiwara, M., & Delabar, J. M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.010 · Cited by 165 · see citing works

Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer’s?

Smith, B. E., Medda, F., Gokhale, V. M., Dunckley, T. L., & Hulme, C. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300094k · Cited by 146 · see citing works

Dyrk1 inhibition improves Alzheimer's disease‐like pathology

Branca, C., Shaw, D. M., Belfiore, R., Gokhale, V. M., Shaw, A. Y., Foley, C., Smith, B. E., Hulme, C., Dunckley, T. L., Meechoovet, B., et al. (2017) · Aging Cell · doi:10.1111/acel.12648 · Cited by 132 · see citing works

An Unbiased Approach to Identifying Tau Kinases That Phosphorylate Tau at Sites Associated with Alzheimer Disease

Cavallini, A., Brewerton, S., Bell, A., Sargent, S., Glover, S., Hardy, C., Moore, R., Calley, J., Ramachandran, D., Poidinger, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.463984 · Cited by 133 · see citing works

Roles of eIF2α kinases in the pathogenesis of Alzheimer’s disease

Ohno, M. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00022 · Cited by 121 · see citing works

A novel DYRK1A (Dual specificity tyrosine phosphorylation‐regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro

Coutadeur, S., Benyamine, H., Delalonde, L., de Oliveira, C., Leblond, B., Foucourt, A., Besson, T., Casagrande, A.-S., Taverne, T., Girard, A., et al. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.13018 · Cited by 120 · see citing works

Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A

Nguyen, T. L., Duchon, A., Manousopoulou, A., Loaëc, N., Villiers, B., Pani, G., Karatas, M., Mechling, A. E., Harsan, L. A., Limanton, E., et al. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.035634 · Cited by 87 · see citing works

Phosphorylation of microtubule‐associated protein tau by AMPK‐related kinases

Yoshida, H., & Goedert, M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07523.x · Cited by 85 · see citing works

RNAi screening of the kinome with cytarabine in leukemias

Tibes, R., Bogenberger, J. M., Chaudhuri, L., Hagelstrom, R. T., Chow, D. C., Buechel, M. E., Gonzales, I. M., Demuth, T., Slack, J. L., Mesa, R. A., et al. (2012) · Blood · doi:10.1182/blood-2011-07-367557 · Cited by 85 · see citing works

Dyrk1A Inhibition as Potential Treatment for Alzheimer’S Disease

Stotani, S., Giordanetto, F., & Medda, F. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0013 · Cited by 78 · see citing works

Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease

Melchior, B., Mittapalli, G. K., Lai, C., Duong‐Polk, K., Stewart, J., Güner, B., Hofilena, B. J., Tjitro, A., Anderson, S., Herman, D. S., et al. (2019) · Aging Cell · doi:10.1111/acel.13000 · Cited by 73 · see citing works

Drosophila Models of Alzheimer's Disease: Advances, Limits, and Perspectives

Bouleau, S., & Tricoire, H. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142802 · Cited by 69 · see citing works

Modulation of Tau Phosphorylation by the Kinase PKR: Implications in Alzheimer's Disease

Bose, A., Mouton‐Liger, F., Paquet, C., Mazot, P., Vigny, M., Gray, F., & Hugon, J. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00437.x · Cited by 68 · see citing works

Tau phosphorylation and neuronal apoptosis induced by the blockade of PP2A preferentially involve GSK3β

Martin, L., Page, G., & Terro, F. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.05.010 · Cited by 65 · see citing works

Roles of Non-Coding RNA in Alzheimer’s Disease Pathophysiology

Olufunmilayo, E. O., & Holsinger, R. M. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512498 · Cited by 66 · see citing works

Advances and perspectives from genetic research: development of biological markers in Alzheimer’s disease

Zetzsche, T., Rujescu, D., Hardy, J., & Hampel, H. J. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.48 · Cited by 61 · see citing works

Altered regulation of tau phosphorylation in a mouse model of down syndrome aging

Sheppard, O., Plattner, F., Rubin, A. N., Slender, A., Linehan, J. M., Brandner, S., Tybulewicz, V. L. J., Fisher, E., & Wiseman, F. K. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.06.025 · Cited by 57 · see citing works

A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer’s disease

Sepulveda-Falla, D., Chavez-Gutierrez, L., Portelius, E., Vélez, J. I., Dujardin, S., Barrera-Ocampo, A., Dinkel, F., Hagel, C., Puig, B., Mastronardi, C., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02249-0 · Cited by 54 · see citing works

Therapeutic approaches in the improvement of cognitive performance in Down syndrome

de la Torre, R., & Dierssen, M. (2012) · Progress in Brain Research · doi:10.1016/b978-0-444-54299-1.00001-7 · Cited by 53 · see citing works

Management of Alzheimer’s disease—An insight of the enzymatic and other novel potential targets

Islam, B. U., & Tabrez, S. S. M. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.01.076 · Cited by 53 · see citing works

Systems Pharmacology

Boran, A. D. W., & Iyengar, R. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20191 · Cited by 49 · see citing works

Developing predictive CSF biomarkers—A challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine

Flood, D. G., Marek, G. J., & Williams, M. J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.01.021 · Cited by 45 · see citing works

Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice

Velazquez, R., Meechoovet, B., Ow, A., Foley, C., Shaw, A., Smith, B., Oddo, S., Hulme, C., & Dunckley, T. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01684-9 · Cited by 37 · see citing works

Tau phosphorylation at Alzheimer's disease-related Ser356 contributes to tau stabilization when PAR-1/MARK activity is elevated

Ando, K., Oka, M., Ohtake, Y., Motoki, H., Shimizu, S., Hisanaga, S., & Iijima, K. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.053 · Cited by 43 · see citing works

The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target

Petyuk, V., Chang, R. R., Ramirez‐Restrepo, M., Beckmann, N. D., Henrion, M., Piehowski, P., Zhu, K., Wang, S., Clarke, J., Huentelman, M. J., et al. (2018) · Brain · doi:10.1093/brain/awy215 · Cited by 39 · see citing works

Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells

Tzeng, Y. T., Liu, P., Li, J., Liu, L.-F., Kuo, S., Hsieh, C.-W., Lee, C., Wu, C.-H., Hsiao, M., Chang, H., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01285 · Cited by 42 · see citing works

REST Regulates DYRK1A Transcription in a Negative Feedback Loop

Lü, M., Zheng, L., Han, B., Wang, L., Wang, P., Liu, H., & Sun, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.174540 · Cited by 39 · see citing works

PKR kinase directly regulates tau expression and Alzheimer's disease‐related tau phosphorylation

Reimer, L., Betzer, C., Kofoed, R. H., Volbracht, C., Fog, K., Kurhade, C., Nilsson, E., Överby, A. K., & Jensen, P. H. (2020) · Brain Pathology · doi:10.1111/bpa.12883 · Cited by 39 · see citing works

Understanding the Multifaceted Role of Human Down Syndrome Kinase DYRK1A

Kay, L. J., Smulders-Srinivasan, T. K., & Soundararajan, M. (2016) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2016.07.001 · Cited by 38 · see citing works

Harmine treatment enhances short-term memory in old rats: Dissociation of cognition and the ability to perform the procedural requirements of maze testing

Mennenga, S. E., Gerson, J. E., Dunckley, T. L., & Bimonte‐Nelson, H. A. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.09.001 · Cited by 36 · see citing works

MicroRNA-23b attenuates tau pathology and inhibits oxidative stress by targeting GnT-III in Alzheimer's disease

Pan, K., Chen, S., Wang, Y., Yao, W., & Gao, X. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108671 · Cited by 35 · see citing works

The new indirubin derivative inhibitors of glycogen synthase kinase‐3, 6‐BIDECO and 6‐BIMYEO, prevent tau phosphorylation and apoptosis induced by the inhibition of protein phosphatase‐2A by okadaic acid in cultured neurons

Martin, L., Magnaudeix, A., Wilson, C. M., Yardin, C., & Terro, F. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22723 · Cited by 34 · see citing works

Application of siRNA in targeting protein expression in kidney disease☆

Stokman, G., Qin, Y., Rácz, Z., Hamar, P., & Price, L. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.07.005 · Cited by 35 · see citing works

Advances with RNA interference in Alzheimer’s disease research

Yuan, W., Chen, S., Ge, X., Chen, Y., Lu, N., & Liu, Z. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s40229 · Cited by 33 · see citing works

The Potential Role of Protein Kinase R as a Regulator of Age-Related Neurodegeneration

Martínez, N. W., Gómez, F. E., & Matus, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.638208 · Cited by 33 · see citing works

Compartmentalized Signaling in Aging and Neurodegeneration

Benedetto, G. D., Iannucci, L. F., Surdo, N. C., Zanin, S., Conca, F., Grisan, F., Gerbino, A., & Lefkimmiatis, K. (2021) · Cells · doi:10.3390/cells10020464 · Cited by 29 · see citing works

Kinase inhibition profiles as a tool to identify kinases for specific phosphorylation sites

Watson, N. A., Cartwright, T. N., Lawless, C., Cámara-Donoso, M., Sen, O., Sako, K., Hirota, T., Kimurâ, H., & Higgins, J. M. G. (2020) · Nature Communications · doi:10.1038/s41467-020-15428-0 · Cited by 30 · see citing works

Discovery of ZJCK-6-46: A Potent, Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor for the Treatment of Alzheimer’s Disease

Chen, H., Gao, X., Li, X., Yu, C., Liu, W., Qiu, J., Liu, W., Geng, H., Zheng, F., Gong, H., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00483 · Cited by 27 · see citing works

Signalling Pathways Implicated in Alzheimer′s Disease Neurodegeneration in Individuals with and without Down Syndrome

Martínez‐Cué, C., & Rueda, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186906 · Cited by 26 · see citing works

High‐Content Screening Identifies Src Family Kinases as Potential Regulators of AR‐V7 Expression and Androgen‐Independent Cell Growth

Szafran, A. T., Stephan, C., Bolt, M. J., Mancini, M. G., Marcelli, M., & Mancini, M. A. (2016) · The Prostate · doi:10.1002/pros.23251 · Cited by 26 · see citing works

Positive contribution of hydroxytyrosol-enriched wheat bread to HbA1c levels, lipid profile, markers of inflammation and body weight in subjects with overweight/obesity and type 2 diabetes mellitus

Binou, P., Stergiou, A., Kosta, O. A., Tentolouris, N., & Karathanos, V. Τ. (2023) · European Journal of Nutrition · doi:10.1007/s00394-023-03133-9 · Cited by 24 · see citing works

Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study

Shahroz, M. M., Sharma, H. K., Altamimi, A. S. A., Alamri, M. A., Ali, A., Ali, A., Alqahtani, S. M., Altharawi, A., Alabbas, A. B., Alossaimi, M. A., et al. (2022) · Molecules · doi:10.3390/molecules27041159 · Cited by 24 · see citing works

Disruption of DYRK1A-induced hyperphosphorylation of amyloid-beta and tau protein in Alzheimer’s disease: An integrative molecular modeling approach

Shukla, R., Kumar, A., Kelvin, D. J., & Singh, T. R. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1078987 · Cited by 22 · see citing works

DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity

Zhu, B., Parsons, T., Foley, C., Shaw, Y., Dunckley, T. L., Hulme, C., & Hodge, J. J. L. (2022) · Scientific Reports · doi:10.1038/s41598-022-19967-y · Cited by 20 · see citing works

DYRK1a Inhibitor Mediated Rescue of Drosophila Models of Alzheimer’s Disease-Down Syndrome Phenotypes

Zhu, B., Parsons, T., Stensen, W., Svendsen, J. S. M., Fugelli, A., & Hodge, J. J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.881385 · Cited by 18 · see citing works

A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer’s disease (AD)

Gehlot, P., Pathak, R., Kumar, S., Choudhary, N. K., & Vyas, V. K. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117925 · Cited by 16 · see citing works

Lipid nanoparticle mediated small interfering RNA delivery as a potential therapy for Alzheimer's disease

Ahmed, T. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16336 · Cited by 16 · see citing works

Exploring the Therapeutic Potential of Noncoding RNAs in Alzheimer’s Disease

Tripathi, S., Sharma, Y., & Kumar, D. (2024) · Protein and Peptide Letters · doi:10.2174/0109298665335550241011080252 · Cited by 15 · see citing works

Glycogen synthase kinase (GSK)-3 and the double-strand RNA-dependent kinase, PKR: When two kinases for the common good turn bad

Piazzi, M., Bavelloni, A., Faenza, I., & Blalock, W. L. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118769 · Cited by 13 · see citing works

Trans-Channel Fluorescence Learning Improves High-Content Screening for Alzheimer's Disease Therapeutics

Wong, D. R., Conrad, J. C., Johnson, N. R., Ayers, J. I., Laeremans, A., Lee, J. C., Lee, J., Prusiner, S. B., Bandyopadhyay, S., Butte, A. J., et al. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-022-00490-8 · Cited by 13 · see citing works

Inkjet printing-based β-secretase fluorescence resonance energy transfer (FRET) assay for screening of potential β-secretase inhibitors of Alzheimer's disease

Lee, J.-M., Samson, A. A. S., & Song, J. M. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.03.033 · Cited by 12 · see citing works

Design, Synthesis, and In Vitro Biological Activities of a Bio-Oxidizable Prodrug to Deliver Both ChEs and DYRK1A Inhibitors for AD Therapy

Barré, A., Azzouz, R., Gembus, V., Papamicaël, C. A., & Levacher, V. (2019) · Molecules · doi:10.3390/molecules24071264 · Cited by 12 · see citing works

Therapeutic Targets in Alzheimer's Disease and Related Tauopathies

Corbo, C. P., & Alonso, A. D. C. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385506-0.00002-8 · Cited by 13 · see citing works

Revisiting the Role of GSK3, A Modulator of Innate Immunity, in Idiopathic Inclusion Body Myositis

Piazzi, M., Bavelloni, A., Cenni, V., Faenza, I., & Blalock, W. L. (2021) · Cells · doi:10.3390/cells10113255 · Cited by 10 · see citing works

A Drug Mystery of Heterocycles: Various Molecules for One Target or One Compound for Multiple Targets?

Shcherbakova, I. M. (2013) · Chemistry of Heterocyclic Compounds · doi:10.1007/s10593-013-1229-x · Cited by 9 · see citing works

MICE DEFICIENT IN AKAP13 (BRX) DEVELOP COMPULSIVE-LIKE BEHAVIOR AND INCREASED BODY WEIGHT

Baig, K. M., Su, S.-C., Mumford, S., Giuliani, E., Ng, S., Armstrong, C. R., Keil, M., Vaught, K. C., Olsen, N., Pettiford, E., et al. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.04.005 · Cited by 8 · see citing works

Straightforward Access to a New Class of Dual DYRK1A/CLK1 Inhibitors Possessing a Simple Dihydroquinoline Core

Ţînţaş, M.-L., Peauger, L., Allix, F., Papamicaël, C. A., Besson, T., Santos, J. S. O., Gembus, V., & Levacher, V. (2022) · Molecules · doi:10.3390/molecules28010036 · Cited by 7 · see citing works

DYRK1A in the physiology and pathology of the neuron-astrocyte axis

Cisternas, P., Kim, J.-Y., Ashfeld, B. L., & Zartman, J. J. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1626062 · Cited by 7 · see citing works

Integrative epigenomic landscape of Alzheimer’s Disease brains reveals oligodendrocyte molecular perturbations associated with tau

Oatman, S. R., Reddy, J. S., Atashgaran, A., Wang, X., Min, Y., Quicksall, Z., Vanelderen, F., Carrasquillo, M. M., Liu, C.-C., Yamazaki, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68864-9 · Cited by 6 · see citing works

Pharmacological approaches to understanding protein kinase signaling networks

Stephenson, E. H., & Higgins, J. M. G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1310135 · Cited by 6 · see citing works

High-Content Screening Approaches That Minimize Confounding Factors in RNAi, CRISPR, and Small Molecule Screening

Haney, S. A. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7357-6_8 · Cited by 6 · see citing works

Methods and approaches to disease mechanisms using systems kinomics

Berard, A. R., Kroeker, A., McQueen, P., & Coombs, K. M. (2017) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2017.12.004 · Cited by 6 · see citing works

Protein quality control of DYRK family protein kinases by the Hsp90-Cdc37 molecular chaperone

Miyata, Y., & Nishida, E. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.119081 · Cited by 6 · see citing works

Beyond Secretases

Medda, F., Smith, B. E., Gokhale, V. M., Shaw, A. Y., Dunckley, T. L., & Hulme, C. (2013) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-417150-3.00005-3 · Cited by 5 · see citing works

Therapeutic Effects of Ashwagandha in Brain Aging and Clock Dysfunction

Jagota, A., & Kukkemane, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-59192-6_21 · Cited by 5 · see citing works

Detecting Biomarkers of Alzheimer’s Disease Based on Multi-constrained Uncertainty-Aware Adaptive Sparse Multi-view Canonical Correlation Analysis

Wang, W., Kong, W., Wang, S., & Wei, K. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01963-y · Cited by 5 · see citing works

In Silico Analysis of Microarray-Based Gene Expression Profiles Predicts Tumor Cell Response to Withanolides

Efferth, T., & Greten, H. J. (2012) · Microarrays · doi:10.3390/microarrays1010044 · Cited by 5 · see citing works

DYRK1A and Parkinson’s disease, facts and hypotheses

Meijer, L., Lindberg, M. F., Hogrel, G., & Khor, B. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107379 · Cited by 2 · see citing works

siRNA high‐throughput kinase library screen identifies protein kinase, DNA‐activated catalytic polypeptide to play a role in MyD88‐induced IFNA2 activation and IL‐8 secretion

Charlaftis, N., Fearon, D. T., Schoenemeyer, A., & Morley, P. J. (2012) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.66 · Cited by 2 · see citing works

The Dual-Specificity Tyrosine Phosphorylation Regulated Kinase 1A and the Advances of Its Inhibitors

王, 勇. (2020) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2020.82006 · Cited by 1 · see citing works

Alterations in protein kinase networks in astrocytes and neurons derived from patients with familial Alzheimer’s DiseasePreprint

Henkel, N., Joyce, A. W., Shedroff, E., Imami, A. S., Alganem, K., Hamoud, A.-R. A., Xu, C., Siciliano, B., Ma, T., Wen, Z., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.14.496149 · Cited by 1 · see citing works

Isogenic human stem cell models reveal mutation-dependent protective mechanisms of APOE3 Christchurch

Frisch, C., Baker, L., Srinivasan, G., Mintah, A. E., Leyasi, S., Pedroza, M., Galyon, B., & Brafman, D. A. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1856154

A Brief Overview of Pathological Tau and Inhibitors and Modifiers of Tau Aggregation for Treatment of Tauopathies

Manthapuri, S. S., & Davis, E. (2021) · Journal of Student Research · doi:10.47611/jsrhs.v10i4.2468

Biotechnology Advances in Disease Treatment

Banesh, S., & Sevda, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00234-9

A Comprehensive Investigation on the Role of Bioactives on DYRK1A to Avert Alzheimer’s Disease

Sharma, M., Mazumder, R., Padhi, S., & Shivangi, K. (2025) · Journal of Natural Remedies · doi:10.18311/jnr/2025/49903

Implication du complexe récepteur 5-HT4/APP/ADAM10 dans la voie non-amyloïdogénique de la maladie d’Alzheimer

Cochet, M. (2011) · theses.fr (ABES) · doi:10.70675/599a8bbez3c0bz407dzbd52z0872ed5f8f6d

Etude du complexe récepteur 5-HT4/ADAM10/APP et recherche de protéines associées à l’ADAM10 : de nouveaux acteurs favorisant la voie non-amyloïdogénique dans le contexte de la maladie d'Alzheimer

Donneger, R. (2014) · theses.fr (ABES) · doi:10.70675/46774734zb996z4960z95d2ze286ee7dbbe3

Longitudinal analysis of brain networks by magnetic resonance imaging (MRI) in a murine model of neuropathic pain-induced depression

Karatas, M. (2019) · theses.fr (ABES) · doi:10.70675/9f5ffcc1z2dfcz4157z8ce5z05964b6bfedf

Mise au point de nouvelles méthodologies de synthèse pour accéder à des molécules hétérocycliques et évaluation de leurs propriétés biologiques dans le domaine du cancer et des maladies neurodégénératives

Zeid, S. B. (2020) · doi:10.70675/dbba0e5fzfefez4231zac75za6c8ff0b9de5

Recherches de biomarqueurs impliqués dans la maladie d’Alzheimer et associés à la protéine DYRK1A dans le syndrome de Down pour valider des traitements potentiels

Gu, Y. (2020) · theses.fr (ABES) · doi:10.70675/ac74aea3z1c11z4272z8737z57c293c54614

Proteostasis maintenance through nanotechnology: Mitigating protein misfolding, mitochondrial impairment, and oxidative stress

Park, J. J., Kuo, G., Khandekar, A., Shin, S., Wang, L., Taneja, T., & Mao, X. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33623-2.00012-x

Dual-specificity tyrosine phosphorylation-regulated kinase 1A in neurodegenerative disorders

Bagheri, S., & Saboury, A. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44173-8.00020-6

BindingDB Entry 50040709: Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.

BindingDB (2013) · UC San Diego · doi:10.7270/q2571d55

BindingDB Entry 50022831: A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer's disease (AD).

BindingDB (2026) · UC San Diego · doi:10.7270/q2c53rpz

BindingDB Entry 50021835: Discovery of ZJCK-6-46: A Potent, Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor for the Treatment of Alzheimer's Disease.

BindingDB (2025) · UC San Diego · doi:10.7270/q2cz3ct4

P3‐024: An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with early Alzheimer's disease

Bose, S., Cavallini, A., Brewerton, S. C., Bell, A., Sargent, S., Glover, S. J., Hardy, C., Moore, R., Calley, J. N., Ramachandran, D., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.1242

An Unbiased Approach to Identifying Tau Kinases That Phosphorylate Tau at Sites Associated with Alzheimer Disease

Cavallini, A., Brewerton, S., Bell, A., Sargent, S., Glover, S., Hardy, C., Moore, R., Calley, J., Ramachandran, D., Poidinger, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.463984 · Cited by 133 · see citing works

Open Access

Azorsa, D. O., Robeson, R. H., Frost, D., hoovet, B. M., Brautigam, G. R., Dickey, C., Beaudry, C. E., Basu, G. D., Holz, D. R., Hern, J. A., et al. (2013)

P2‐149: The role of protein kinase A in coordinating tau phosphorylation state relevant to Alzheimer's disease

Seereeram, A., Siemann, M., Anderton, B. H., & Hanger, D. P. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.1222

P2‐141: Unraveling the process of tau hyperphosphorylation one gene at a time

Robeson, R. H., Brautigam, G. R., Frost, D., Azorsa, D. O., Dickey, C. A., Beaudry, C. E., Basu, G. D., Holz, D. R., Hernandez, J., Bisanz, K. M., et al. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.1214